Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life
Overview
Authors
Affiliations
Background: Systematic assessment of severe asthma can be used to confirm the diagnosis, identify comorbidities, and address adherence to therapy. However, the prospective usefulness of this approach is yet to be established. The objective of this study was to determine whether the systematic assessment of severe asthma is associated with improved quality of life (QoL) and health-care use and, using prospective data collection, to compare relevant outcomes in patients referred with severe asthma to specialist centers across the United Kingdom.
Methods: Data from the National Registry for dedicated UK Difficult Asthma Services were used to compare patient demographics, disease characteristics, and health-care use between initial assessment and a median follow-up of 286 days.
Results: The study population consisted of 346 patients with severe asthma. At follow-up, there were significant reductions in health-care use in terms of primary care or ED visits (66.4% vs 87.8%, P < .0001) and hospital admissions (38% vs 48%, P = .0004). Although no difference was noted in terms of those requiring maintenance oral corticosteroids, there was a reduction in steroid dose (10 mg [8-20 mg] vs 15 mg [10-20 mg], P = .003), and fewer subjects required short-burst steroids (77.4% vs 90.8%, P = .01). Significant improvements were seen in QoL and control using the Asthma Quality of Life Questionnaire and the Asthma Control Questionnaire.
Conclusions: To our knowledge, this is the first time that a prospective study has shown that a systematic assessment at a dedicated severe asthma center is associated with improved QoL and asthma control and a reduction in health-care use and oral steroid burden.
Health system characteristics and evidence-based asthma care.
Crawford A, Jones G, Scullion J, Ryan D, Blakey J Front Allergy. 2025; 6:1528526.
PMID: 40065833 PMC: 11891166. DOI: 10.3389/falgy.2025.1528526.
Meng G, Cui H, Feng C, Guo C, Song L, Duan Z PLoS One. 2025; 20(1):e0317587.
PMID: 39820222 PMC: 11737801. DOI: 10.1371/journal.pone.0317587.
Carretero Gracia J, Cebollero Rivas P Open Respir Arch. 2024; 7(1):100376.
PMID: 39717140 PMC: 11664392. DOI: 10.1016/j.opresp.2024.100376.
Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED.
Meys R, Franssen F, van t Hul A, Bakke P, Caruso M, Dahlen B Health Qual Life Outcomes. 2024; 22(1):109.
PMID: 39707320 PMC: 11662558. DOI: 10.1186/s12955-024-02321-3.
Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK.
Damery S, Jones J, Idris E, Cooper A, Minshall H, Clowes C NPJ Prim Care Respir Med. 2024; 34(1):7.
PMID: 38693173 PMC: 11063170. DOI: 10.1038/s41533-024-00365-y.